{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T17:15:06Z","timestamp":1790874906770,"version":"4.1.0"},"reference-count":20,"publisher":"European Respiratory Society (ERS)","issue":"4","license":[{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"SarcoidosisUK"}],"content-domain":{"domain":["publications.ersnet.org"],"crossmark-restriction":true},"short-container-title":["ERJ Open Res"],"accepted":{"date-parts":[[2020,9,9]]},"published-print":{"date-parts":[[2020,10]]},"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Chronic cough is a distressing symptom for many people with pulmonary sarcoidosis. Continuous treatment with a macrolide antibiotic may improve cough. We aimed to assess the potential efficacy of azithromycin in patients with sarcoidosis and self-reported cough.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We conducted a noncontrolled, open-label clinical trial of azithromycin 250\u2005mg once daily for 3\u2005months in patients with pulmonary sarcoidosis who reported a chronic cough. The primary outcome was number of coughs in 24\u2005h. Secondary outcomes were cough visual analogue scales and quality of life measured using the Leicester Cough Questionnaire and King's Sarcoidosis Questionnaire. Safety outcomes included QTc interval on ECG. Measurements were made at baseline and after 1 and 3\u2005months of treatment.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>All 21 patients were white, median age 57\u2005years, 9 males, 12 females, median 3 years since diagnosis. Four were taking oral corticosteroids and none were taking other immunosuppressants. Twenty patients completed the trial. The median (range) number of coughs in 24\u2005h was 228 (43\u20131950) at baseline, 122 (20\u2013704) at 1\u2005month, and 81 (16\u2013414) at 3 months (p=0.002, Friedman's test). The median reduction in cough count at 3\u2005months was 49.6%. There were improvements in all patient-reported outcomes. Azithromycin was well tolerated.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>In a noncontrolled open-label trial in people with sarcoidosis who reported a chronic cough, 3\u2005months of treatment with azithromycin led to improvements in a range of cough metrics. Azithromycin should be tested as a treatment for sarcoidosis cough in a randomised placebo-controlled trial.<\/jats:p><\/jats:sec>","DOI":"10.1183\/23120541.00534-2020","type":"journal-article","created":{"date-parts":[[2020,10,15]],"date-time":"2020-10-15T18:55:14Z","timestamp":1602788114000},"page":"00534-2020","update-policy":"https:\/\/doi.org\/10.1183\/ers-crossmark-policy","source":"Crossref","is-referenced-by-count":20,"title":["Azithromycin for sarcoidosis cough: an open-label exploratory clinical trial"],"prefix":"10.1183","volume":"6","author":[{"given":"Simon D.","family":"Fraser","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susannah","family":"Thackray-Nocera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marica","family":"Shepherd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"Flockton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Wright","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wayne","family":"Sheedy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kayleigh","family":"Brindle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alyn H.","family":"Morice","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul M.","family":"Kaye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael G.","family":"Crooks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4606-9559","authenticated-orcid":false,"given":"Simon P.","family":"Hart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"81","published-online":{"date-parts":[[2020,10,15]]},"reference":[{"key":"2024101710532227000_6.4.00534-2020.1","doi-asserted-by":"publisher","DOI":"10.1186\/1745-9974-9-9"},{"key":"2024101710532227000_6.4.00534-2020.2","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01369-2015"},{"key":"2024101710532227000_6.4.00534-2020.3","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01136-2019"},{"key":"2024101710532227000_6.4.00534-2020.4","doi-asserted-by":"publisher","DOI":"10.1136\/thoraxjnl-2019-213929"},{"key":"2024101710532227000_6.4.00534-2020.5","doi-asserted-by":"publisher","DOI":"10.1186\/1745-9974-2-8"},{"issue":"Suppl. 59","key":"2024101710532227000_6.4.00534-2020.6","first-page":"PA832","article-title":"A comparison of two scoring methods for the King's sarcoidosis questionnaire","volume":"46","author":"Sinha","year":"2015","journal-title":"Eur Respir J"},{"key":"2024101710532227000_6.4.00534-2020.7","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-540-79842-2_16"},{"issue":"Suppl. 56","key":"2024101710532227000_6.4.00534-2020.8","first-page":"P699","article-title":"Assessing sarcoidosis: the King's sarcoidosis questionnaire and the minimal important difference","volume":"40","author":"Patel","year":"2012","journal-title":"Eur Respir J"},{"key":"2024101710532227000_6.4.00534-2020.9","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00218613"},{"key":"2024101710532227000_6.4.00534-2020.10","doi-asserted-by":"crossref","first-page":"856","DOI":"10.4168\/aair.2019.11.6.856","article-title":"Inhaled corticosteroids and placebo treatment effects in adult patients with cough: a systematic review and meta-analysis","volume":"11","author":"Lee","year":"2019","journal-title":"Allergy Asthma Immunol Res"},{"key":"2024101710532227000_6.4.00534-2020.11","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.99.13613519"},{"key":"2024101710532227000_6.4.00534-2020.12","doi-asserted-by":"publisher","DOI":"10.1186\/1465-9921-14-125"},{"key":"2024101710532227000_6.4.00534-2020.13","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1016\/j.chest.2015.12.036","article-title":"The effects of azithromycin in treatment-resistant cough: a randomized, double-blind, placebo-controlled trial","volume":"149","author":"Hodgson","year":"2016","journal-title":"Chest"},{"key":"2024101710532227000_6.4.00534-2020.14","doi-asserted-by":"publisher","DOI":"10.1136\/thoraxjnl-2018-212102"},{"key":"2024101710532227000_6.4.00534-2020.15","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1016\/S2213-2600(17)30310-7","article-title":"A novel formulation of inhaled sodium cromoglicate (PA101) in idiopathic pulmonary fibrosis and chronic cough: a randomised, double-blind, proof-of-concept, phase 2 trial","volume":"5","author":"Birring","year":"2017","journal-title":"Lancet Respir Med"},{"key":"2024101710532227000_6.4.00534-2020.16","doi-asserted-by":"publisher","DOI":"10.1136\/thorax.56.5.336"},{"key":"2024101710532227000_6.4.00534-2020.17","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201402-0385CI"},{"key":"2024101710532227000_6.4.00534-2020.18","doi-asserted-by":"crossref","first-page":"e4518","DOI":"10.1097\/MD.0000000000004518","article-title":"Prevalence of cardiac sarcoidosis in white population: a case-control study: proposal for a novel risk index based on commonly available tests","volume":"95","author":"Martusewicz-Boros","year":"2016","journal-title":"Medicine"},{"key":"2024101710532227000_6.4.00534-2020.19","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1001\/jamadermatol.2013.4646","article-title":"Oral antimycobacterial therapy in chronic cutaneous sarcoidosis: a randomized, single-masked, placebo-controlled study","volume":"149","author":"Drake","year":"2013","journal-title":"JAMA Dermatol"},{"key":"2024101710532227000_6.4.00534-2020.20","first-page":"201","article-title":"Effects of broad-spectrum antimycobacterial therapy on chronic pulmonary sarcoidosis","volume":"30","author":"Drake","year":"2013","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"}],"container-title":["ERJ Open Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1183\/23120541.00534-2020","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,24]],"date-time":"2025-02-24T05:04:26Z","timestamp":1740373466000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.ersnet.org\/lookup\/doi\/10.1183\/23120541.00534-2020"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10]]},"references-count":20,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2020,11,10]]},"published-print":{"date-parts":[[2020,10]]}},"alternative-id":["10.1183\/23120541.00534-2020"],"URL":"https:\/\/doi.org\/10.1183\/23120541.00534-2020","relation":{},"ISSN":["2312-0541"],"issn-type":[{"value":"2312-0541","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10]]}}}